Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 3/20 | 0.63 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.63 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 2/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | MAOA | P21397 | 2/20 | 0.63 |
| ▸ | CA4 | P22748 | 2/20 | 0.63 |
| ▸ | CA6 | P23280 | 2/20 | 0.63 |
| ▸ | CA5A | P35218 | 2/20 | 0.63 |
| ▸ | CA7 | P43166 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | POU5F1 | Q01860 | 2/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.63 |
| ▸ | SLC47A2 | Q86VL8 | 2/20 | 0.63 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.63 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL11385711 | 0.93 | HRH2 (0.56) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL188452 | 0.90 | HRH2 (0.67) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11382761 | 0.89 | HRH2 (0.60) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11393006 | 0.87 | HRH2 (0.58) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11389410 | 0.84 | HRH2 (0.62) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11246474 | 0.83 | HRH2 (0.60) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Hydrochloric Acid SCHEMBL11249059 | 0.82 | HRH2 (0.59) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11378486 | 0.81 | CA2 (0.54) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL11380940 | 0.81 | HRH2 (0.40) | HRH2SLC22A2CA12SLC22A3CA1 | |
| SCHEMBL16386284 | 0.81 | HRH2 (0.66) | HRH2SLC22A2CA12SLC22A3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4283408-A | Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1981-08-11 | — | — | US | claimed |
| WO-2021183259-A1 | FAMOTIDINE AND FAMOTIDINE ANALOGS FOR CORONA VIRUS TREATMENT | Nanopharmaceutics, Inc. (US) | 2021-09-16 | — | — | WO | disclosed |
| US-20140220057-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220079-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220105-A1 | TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-4283408-A | Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1981-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220105-A1 | TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MICA | HRH2 4573/4885SLC22A2 1951/4885CA12 574/4885 |
| US-20140220057-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MUC1 | HRH2 3391/4885SLC22A2 422/4885CA12 121/4885 |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MICA | HRH2 3944/4885SLC22A2 898/4885CA12 256/4885 |
| US-20140220079-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, ERBB2, TLR5 | HRH2 178/4885SLC22A2 2174/4885CA12 165/4885 |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, TAP1, MICA | HRH2 3453/4885SLC22A2 1026/4885CA12 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.